By otakuyassine3@gmail.com 
Greenfield Savings Bank reduced its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 1.1% in the 4th quarter, Holdings Channel reports. The fund owned 10,631 shares of the company’s stock after selling 113 shares during the period. Greenfield Savings Bank’s holdings in Johnson & Johnson were worth $1,537,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently bought and sold shares of JNJ. Cullen Investment Group LTD. boosted its holdings in shares of Johnson & Johnson by 1.8% during the fourth quarter. Cullen Investment Group LTD. now owns 69,619 shares of the company’s stock worth $10,068,000 after purchasing an additional 1,253 shares during the period. Tealwood Asset Management Inc. lifted its position in Johnson & Johnson by 2.9% in the 4th quarter. Tealwood Asset Management Inc. now owns 15,993 shares of the company’s stock worth $2,313,000 after buying an additional 458 shares in the last quarter. Grandview Asset Management LLC acquired a new stake in shares of Johnson & Johnson during the 4th quarter valued at $1,099,000. Traveka Wealth LLC grew its holdings in shares of Johnson & Johnson by 216.1% during the 4th quarter. Traveka Wealth LLC now owns 6,367 shares of the company’s stock valued at $921,000 after acquiring an additional 4,353 shares in the last quarter. Finally, BCS Wealth Management purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth $560,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.
Insider Transactions at Johnson & Johnson
In other Johnson & Johnson news, Director Mark A. Weinberger purchased 1,000 shares of the company’s stock in a transaction that occurred on Thursday, December 12th. The stock was purchased at an average cost of $147.22 per share, with a total value of $147,220.00. Following the acquisition, the director now directly owns 1,000 shares of the company’s stock, valued at approximately $147,220. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Company insiders own 0.16% of the company’s stock.
Wall Street Analyst Weigh In
A number of brokerages have commented on JNJ. Wells Fargo & Company boosted their target price on Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 16th. Citigroup dropped their price objective on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. Bank of America reiterated a “neutral” rating and issued a $166.00 target price on shares of Johnson & Johnson in a research note on Tuesday, December 10th. Wolfe Research started coverage on shares of Johnson & Johnson in a report on Friday, November 15th. They set an “outperform” rating and a $190.00 price target on the stock. Finally, Royal Bank of Canada upped their price objective on shares of Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a report on Wednesday, October 16th. Seven equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $174.71.
View Our Latest Analysis on JNJ
Johnson & Johnson Trading Up 0.1 %
JNJ stock opened at $144.68 on Wednesday. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The firm has a market cap of $348.33 billion, a P/E ratio of 20.94, a P/E/G ratio of 2.52 and a beta of 0.51. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $168.85. The business’s 50 day moving average is $149.12 and its 200-day moving average is $156.09.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. The company had revenue of $22.47 billion during the quarter, compared to analysts’ expectations of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The business’s revenue was up 5.2% on a year-over-year basis. During the same period last year, the business earned $2.66 earnings per share. Equities analysts anticipate that Johnson & Johnson will post 9.94 earnings per share for the current fiscal year.
Johnson & Johnson Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be given a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.43%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 71.78%.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Featured Stories
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.